Prevalence and risk factors of anti-tuberculosis drug-induced hepatitis in Malaysia

Singapore Medical Journal

Volumn 49, Issue 9, 2008, Pages 688-693

  Marzuki, O A ^a,b   Fauzi, A R M ^b   Ayoub, S ^b   Kamarul Imran, M ^b  

^a SCHOOL OF MEDICAL SCIENCES   (Malaysia)

^b INTERNATIONAL ISLAMIC UNIVERSITY MALAYSIA   (Malaysia)

Author keywords

Anti tuberculosis drugs; Drug induced hepatitis; Extrapulmonary tuberculosis; Hepatoxicity; Isoniazid; Pyrazinamide; Rifampin; Toxic hepatitis

Indexed keywords

ALBUMIN; GLOBULIN; ISONIAZID; PYRAZINAMIDE; RIFAMPICIN; STREPTOMYCIN; TUBERCULOSTATIC AGENT;

ADULT; ALBUMIN BLOOD LEVEL; ANTIBIOTIC THERAPY; ARTICLE; CASE CONTROL STUDY; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; COMORBIDITY; CONTROLLED STUDY; DIRECTLY OBSERVED THERAPY; DRUG INDUCED DISEASE; EXTRAPULMONARY TUBERCULOSIS; FEMALE; HEPATITIS B; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER FUNCTION TEST; LIVER TOXICITY; LOGISTIC REGRESSION ANALYSIS; LUNG TUBERCULOSIS; MALAYSIA; MALE; MONOTHERAPY; OBSERVATIONAL STUDY; PATIENT COMPLIANCE; PREVALENCE; RETROSPECTIVE STUDY; RISK FACTOR; TOXIC HEPATITIS; TUBERCULOSIS; TUBERCULOSIS CONTROL;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTITUBERCULAR AGENTS; CASE-CONTROL STUDIES; FEMALE; HEPATITIS, TOXIC; HIV INFECTIONS; HUMANS; MALAYSIA; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK FACTORS; TUBERCULOSIS;

EID: 54349104219     PISSN: 00375675     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Snider Jr DE, Roper WL. The new tuberculosis. N Engl J Med 1992; 326:703-5.
2. World Health Organization. Tuberculosis. Fact Sheet No. 104 (revised April 2005). Available at: www.who.int/mediacentre/factsheets/fs104/en/index. html. Accessed July 10, 2006.
3. Ministry of Health (MOH), Malaysia and Academy of Medicine of Malaysia (AMM). Practice Guidelines for the Control and Management of Tuberculosis. 2nd ed. Kuala Lumpur: MOH/AMM, 2002.
4. Aithal PG, Day CP. The natural history of histologically proved drug induced liver disease. Gut 1999; 44:731-5.
5. Parthasarathy R, Sarma GR, Janardhanam B, et al. Hepatic toxicity in South Indian patients during treatment of tuberculosis with short-course regimens containing isoniazid, rifampicin and pyrazinamide. Tubercle 1986; 67:99-108.
6. Türktaş H, Ünsal M, Tülek N, Örüç O. Hepatotoxicity of antituberculosis therapy (rifampicin, isoniazid and pyrazinamide) or viral hepatitis. Tubercle Lung Dis 1994; 75:58-60.
7. Combs DL, O'Brien RJ, Geiter LJ. USPHS tuberculosis short-course chemotherapy trial 21: Effectiveness, toxicity and acceptability. The report of final results. Ann Intern Med 1990; 112:397-406.
8. British Thoracic Society and Tuberculosis Association. Short course chemotherapy in pulmonary tuberculosis. Lancet 1975; 305:119-24.
9. Snider DE, Long MW, Cross FS, Farer LS. Six months isoniazid and rifampicin therapy for pulmonary tuberculosis: report of a United States Public Health Service cooperative trial. Am Rev Respir Dis 1984; 129:573-9.
10. Steele MA, Burk RF, DesPrez RM. Toxic hepatitis with isoniazid and rifampin: a meta-analysis. Chest 1991; 99:465-71.
11. Teleman MD, Chee CB, Earnest A, et al. Hepatotoxicity of tuberculosis chemotherapy under a general program conditions in Singapore. Int J Tuberc Lung Dis 2002; 6:699-705.
12. Centers for Disease Control. National consensus conference on tuberculosis. Preventive treatment of tuberculosis. Chest 1985; 87:128-32.
13. Grönhagen-Riska C, Hellstrom P-E, Fröseth B. Predisposing factors in hepatitis induced by Isoniazid-Rifampin treatment of tuberculosis. Am Rev Respir Dis 1978; 118:461-6.
14. Wu JC, Lee SD, Yeh PF. Isoniazid, rifampicin induced hepatitis in hepatitis B carriers. Gastroenterol 1990; 98:502-4.
15. Kumar A, Misra PK, Mehotra R, Govil YC, Rana GS. Hepatotoxicity of rifampicin and isoniazid: is it all drug-induced hepatitis? Am Rev Respir Dis 1991; 143:1350-2.
16. Pande JN, Singh SPN, Khilnani GC, Khilnani S, Tandon RK. Risk factors for hepatotoxicity from antituberculosis drugs: a case-control study. Thorax 1996; 51:132-6.
17. Gurumurthy P, Krishnamurthy MS, Nazareth O, et al. Lack of relationship between hepatic toxicity and acetylator phenotypes in 3000 south Indian patients during treatment with isoniazid for tuberculosis. Am Rev Respir Dis 1984; 129:58-61.
18. Sharma SK, Balamurugan A, Saha PK, Pandey RM, Mehra NK. Evaluation of clinical and immunogenetic risk factors for the development of hepatotoxicity during antituberculosis treatment. Am J Respir Crit Care Med 2002; 166:916-9.
19. Ungo JR, Jones D, Ashkin D, et al. Antituberculosis drug-induced hepatotoxicity. Am J Respir Crit Care Med 1998; 157:1871-6.
20. Fauzi ARM, Shah A, Rathor MY, Satwi S. Risk Factors for Anti Tuberculous Drugs Induced Hepatitis: A prospective survey from a chest clinic in a general hospital. Med J Malaysia 2004; 59:72-7.
21. Mehta S. Malnutrition and drugs: clinical implications. Dev Pharmacol Ther 1990; 15:159-65.
22. Ozick LA, Jacob L, Comer GM, et al. Hepatotoxicity from isoniazid and rifampin in inner-city AIDS patients. Am J Gastroenterol 1995; 90:1978-80.
23. Novak D, Lewis JH. Drug-induced liver disease. Curr Opin Gastroenterol 2003; 19:203-15.
24. Ohkawa K, Hashiguchi M, Ohno K, et al. Risk factors for antituberculous chemotherapy-induced hepatotoxicity in Japanese pediatric patients. Clin Pharmacol Ther 2002; 72:220-6.
25. Lee BH, Koh W-J, Choi MS, et al. Inactive Hepatitis B surface antigen carrier state and hepatotoxicity during antituberculosis chemotherapy. Chest 2005; 127:1304-11.
26. Døssing M, Wilcke JTR, Askgaard DS, Nybo B. Liver injury during antituberculosis treatment: an 11-year study. Tubercle Lung Dis 1996; 77:335-40.
27. Singh J, Garg PK, Tandon RK. Hepatotoxicity due to anti tuberculosis therapy: clinical profile and reintroduction of therapy. J Clin Gastroenterol 1996; 22:211-4.
28. Hwang SJ, Wu JC, Lee CN, et al. A prospective clinical study of isoniazid-rifampicin-pyrazinamide-induced liver injury in an area endemic for hepatitis B. J Gastroenterol Hepatol 1997; 12:87-91.